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Secondary hyperparathyroidism and cardiac hypertrophy in hemodi-
alysis patients. Echocardiographic assessment of left ventricular func-
tion was performed in 66, stable hemodialysis patients and 50 normal
controls matched for sex, age and arterial blood pressure. On the basis
of bone histology, hemodinlysis patients were classified into two
groups: (I) patients with normal bone resorption; and (2) patients with
active secondary hyperparathyroidism characterized by an increased
bone resorption. Left ventricular function of these two subgroups were
compared together as well as with the echocardiographic characteristics
of normal controls. In comparison with normal controls, hemodialysis
patients with normal bone resorption had an increased left ventricular
volume (P < 0.001) and left ventricular mass (P <0.001) with a similar
left ventricular mass-to-volume ratio. Their systolic arterial pressure—
mass-to-volume ratio correlation was similar to that of normal controls,
indicating an adequate myocardial hypertrophy. Patients with increased
bone resorption had high parathormone and alkaline phosphatase
levels; though the left ventricular dilation was similar to that of
hemodialysis patients with normal bone resorption, the left ventricular
mass was lower (P < 0.001) and was similar to the left ventricular mass
of normal controls. In addition, patients with increased bone resorption
had a lower mass-to-volume ratio (P < 0.001) and their systolic arterial
pressure—mass-to-volume ratio correlation exhibited a significant down-
ward shift (P C 0.001), suggesting an inadequate myocardial hypertro-
phy. Patients with increased bone resorption and secondary hyperpara-
thyroidism had an increased heart rate, a higher systolic arterial
pressure and end-systolic stress. Furthermore, they had an increased
velocity of fiber shortening (P C 0.01) and shorter left ventricular
ejection time (P cc 0.001). In summary, present data suggest the
possibility that parathormone may exert myocardial effects in hemodi-
alysis patients.
Cardiovascular complications are the leading cause of mor-
tality in patients on maintenance dialysis [1, 2], with ischemic
heart disease as the major single reason for such high mortality.
However, other factors which adversely affect cardiac function
are also present in these patients. Thus, uremic serum has a
depressant and toxic effect on the myocardium [3—5]; however,
the specific uremic toxin responsible for these adverse effects
has not been identified. In addition, parathyroid hormone
(PTH) has been shown to be a potent uremic toxin [6] which, in
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experimental conditions, has adverse effects on myocardium
cells [7—9]. Finally, in dialysis patients, secondary hyperpara-
thyroidism has been implicated in the pathogenesis of the left
ventricular abnormalities [10]. Available data concerning the
myocardial functional impact of hyperparathyroidism in dialy-
sis patients are not conclusive. Thus, in some studies, left
ventricular dysfunction [11] and an improvement of myocardial
performance after parathyroidectomy [121 was observed. Other
studies have failed to demonstrate impaired cardiac perform-
ance [10, 13]. The purpose of the present study is to assess, in
a large group of stable maintenance dialysis patients, the
relationship between left ventricular function, and the severity
of secondary hyperparathyroidism as assessed by bone histol-
ogy and PTH.
Methods
Patient selection
One hundred and thirty-five patients on maintenance dialysis
were evaluated for at least 18 months. Patients were on dialysis
from 18 to 204 months (88.2 50.4). However, after a final
evaluation, only 66 patients (34 male and 32 female) were
included in this study. Patients were excluded from the study
because of: (a) history of angina pectoris, myocardial infarc-
tion, or congestive heart failure; (b) non-compliancy in fluid
intake (interdialytic body weight gain greater than 5% of "dry
weight"); (c) presence of valvular heart disease; (d) diabetes,
systemic diseases, blood lipid abnormalities, and iron overload;
(e) left ventricular wall motion abnormalities (identified by
two-dimensional echocardiography); (t) a history of malignant
hypertension and primary hypertensive heart disease; and (g)
presence of hypertension while on dialysis, that is, patients
whose blood pressure was not controlled with ultrafiltration
during dialysis and who needed antihypertensive drug therapy.
Eleven patients were excluded because their echo-tracings
were technically unsatisfactory.
Fifty healthy subjects (26 male and 24 female) with normal
renal function were studied as controls. They were matched for
sex, age and arterial blood pressure with hemodialysis patients.
Their cardiovascular status was normal as evaluated by clinical
history, ECG and chest X-ray. The control subjects were not
taking cardiovascular drugs. All patients and control subjects
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gave informed consent and protocol was approved by Institut
National de Ia Sante et de Ia Recherche Medicate (INSERM).
The dialysis patients were dialyzed three times per week and
the duration of dialysis was individually tailored (4 to 5 hours)
to control body fluids and to maintain the predialysis serum
urea less than 30 mmollliter, serum creatinine less than 1.1
mmollliter and serum electrolytes within normal range. Dialytic
therapy was performed using a hollow fiber dialyzer, whose
surface (1.2 to 2.0 m2) was matched to patient's body surface-
area. Dialysate water was treated with reverse osmosis. Dialy-
sate was delivered by a system which included bicarbonate
delivery and ultrafiltration devices. Internal arteriovenous (A-V)
fistula was used as vascular access in all patients. Vitamin and
iron supplements were prescribed routinely. Phosphate binders
were given when necessary in appropriate dose, aiming to
maintain pre-dialysis phosphate concentration less than 2.0
mmol/liter. No patients were taking cardiovascular drugs. Rou-
tine biochemical parameters determined by standard methods
included hematocrit, hemoglobin, blood urea, serum creatinine,
potassium, bicarbonate, total protein, total calcium and ionized
calcium, cholesterol, and triglycerides. Serum aluminum was
measured by atomic absorption spectrophotometry and graph-
ite furnace. The normal values of serum aluminum, determined
in 20 normal subjects, were 0.18 0.06 jsmol/liter.
Blood pressure and echocardia graphic measurements
Blood pressure was measured by a mercury sphygmomanom-
eter, using the first and filth phases of the Korotkoff sounds.
The pressures were measured in supine and upright position
before and after each dialysis. Only the supine values are
reported. The influence of blood pressure on left ventricular
mass (LVM) is well known; however, in general, the correla-
tions between LVM and a single blood pressure is weak [141.
On the other hand, "absolute" blood pressure defined as the
average 24 hours obtained by pressure monitoring or serial
measurements, correlates much better with LVM [14]. There-
fore, to evaluate the long—term blood pressure profile in dialysis
patients, the blood pressure was defined as the mean value of all
blood pressure measurements done in supine position before
and after dialysis during a period of six months preceding the
echocardiographic study. For the evaluation of hemodynamic
parameters such as effects of A-V fistula occlusion and end-
systolic stress, a casual blood pressure measured during echo-
cardiographic study was used. In normal controls, blood pres-
sure was evaluated twice a month over a period of three
months. The average value of the six measurements (supine
position) was taken for each subject.
Echocardiographic studies were performed 15 to 20 hours
after the midweek hemodialysis treatment and were repeated in
all patients after 10 minutes of manual occlusion of the A-V
fistula in order to assess hemodynamic effect. Two-dimensional
echocardiography was performed using Roche Kontron R.T.
400 apparatus (Roche Laboratories, Nutley, New Jersey, USA).
M-mode echocardiography was done with an IRREX ultraso-
nograph using a 2.25 MHz transducer and a Cardio 80 Hewlett
Packard computer (Elkhart, Indiana, USA). Echocardiograms
were obtained with the patients in semi-recumbent and left
lateral positions from an echocardiographic window located in
the third or fourth intercostal space at the left sternal border.
Echocardiographic data were calculated on at least 10 high-
quality cycles. Left ventricular measurements were made,
according to the recommendations of the American Society of
Echocardiography [15] and Penn conventions [16]. Left ventric-
ular end-diastolic dimension (LVEDiD), interventricular septal
thickness (IVST), and posterior wall thickness (LVPWT) made
according to Penn convention were used to calculate the LVM
1161:
LVM (g) = 1.04 [(LVEDiD + IVST + LVPWT)3 —
(LVEDiD)3]
For the estimation of left ventricular diastolic volume (LVV),
the formula (LVEDiD)3 was used [16]. Mean arterial pressure
was defined as the sum of diastolic pressure with one—third of
the pulse pressure. M-mode echographic aortic valve-motion
was used to assess the left ventricular ejection time. The mean
velocity of circumferential fiber shortening (VCF) was calcu-
lated using the method of Cooper et al [17]. End-systolic stress
was calculated according to Devereux et al [18] with the use of
left ventricular end-systolic diameter, end-systolic posterior
wall thickness and casual arterial systolic blood pressure.
Secondary hyperparathyroidism in dialyzed patients
The severity of secondary hyperparathyroidism was evalu-
ated biochemically with measurements of serum calcium, phos-
phate, alkaline phosphatase and immunoreactive parathyroid
hormone (iPTH). Histologically, secondary hyperparathyroid-
ism was evaluated by assessing the severity of osteoclastic bone
resorption on bone biopsy. Biochemical parameters were deter-
mined by standard laboratory methods. PTH was determined by
radioimmunoassay (Kit hPTH-C-K; Compagnie ORIS Industrie)
using a specific 53-84 antiserum against the C-terminal fragment
of synthetic human PTH [19]. The value obtained in normal
population range was from 20 to 90 pg/mi.
The 66 patients included in this study had anterior iliac, crest
bone biopsy, which was performed after double tetracycline
labeling according to the schedule of two days on tetracycline,
ten days off, and two days on. On three 5 j sections stained by
toluidin blue, trabecular bone volume (%), osteoid surfaces and
volume (%), osteoblastic surfaces (%), osteoclastic resorption
surfaces (%), osteoclasts (/mm2) were assessed. On two un-
stained 10 s thick sections, the mineralization rate and the
extent of single or double labeled surfaces (%) were evaluated.
All measurements were performed with an eye-piece graticule
(Zeiss integral plate II, Zeiss, Oberkochen, FRG). Normal
values from the laboratory were obtained from 23 normal
subjects [201. On the basis of the severity of osteoclastic bone
resorption-surfaces [211, patients were divided into two groups:
those with significant increase in bone resorption characteristic
of osteitis fibrosa (OF) and those with minimal or normal bone
resorption (NBR). Normal value of osteociastic resorption
surfaces are 0.60 0.10%. Maximum normal value was deter-
mined as 0.60 + 4 SD, that is, 1.0%. Patients above this value
were classified as OF, and patients below this value as NBR.
Values are expressed as mean SD. Student's t-test was used
for group comparison. Multigroup comparison were done using
analysis of variance followed by t-tests. An overall level of
significance less than 0.05 was obtained by Bonferonni adjust-
ment (P < 0.02 was necessary). Univariate and multivariate
regression analysis were done for correlation studies, using
902 London et a!
Creatinine g.tmoi/liter 983 134 987 128
Calcium mmoi/lUer 2.44 0.13 2.42 0.12
Ionized calcium mmo//ijter 1.05 0.06 1.04 0.09
Phosphates mmo!/iiter 1.91 0.23 1.77 0.28
Alkaline phosphatase nKat/iiter 1555 509 791 187U
Plasma proteins g/iiter 69.7 2.6 69.1 2.7
Hemoglobin mmoi/iiter 5.5 1.7 5.2 1.7
CO2 combining power mmoi/iiter 19.8 1.7 19.20 1.75
Serum parathyroid hormone pg/mI 566 181 148.3 60.Oa
Serum aluminum p.'noi/iiter 1.47 1.03 1.95 1.00
Values are mean SD. Abbreviations are: OF, osteitis fibrosa; NBR,
normal bone resoprtion.& <0.001
Table 2. Bone histomorphometric data of controls and dialysis
patients with OF and NBR
Controls
Dialysis
OF
Dialysis
NBR
Osteoclastic resorption %
Osteoclasts number/mm2
0.60 0.10
0.18 0.08
4.21 2.90a
2.91 1.76k
0.40 0.20
0.26 0.22
Osteoblastic surfaces % 2.9 0.7 13.3 6.2a 3.5 3.5
Tetracycline double- 5.0 0.6 15.2 g7a 5.2 3.7
labeled surface %
Table 3. Echocardiographic measurements in control subjects and hemodialysis patients with OF and NBR
Values are mean SD. Abbreviations are: LV,
shortening.
least-square method. Covariance analysis was used to estimate
the differences in the correlations.
Results
Left ventricular function in patients with osteitis fibrosa and
normal bone resorption
The biochemical parameters of dialysis patients with osteitis
fibrosa (OF group) and those with normal bone resorption
(NBR group), are displayed in Table 1. There were obvious
biochemical abnormalities in these patients mostly due to the
end-stage renal disease status of hemodialysis patients. The
only significant biochemical difference between the two groups
of dialysis patients was the higher level of serum alkaline
phosphatase and iPTH observed in patients with osteitis fibrosa
(P < 0.001).
Table 2 displays bone histomorphometric parameters evalu-
ated in both groups of dialysis patients and control subjects.
While there were no significant differences in any parameters
between the control group and the NBR group, obviously
patients with OF had significant histomorphometric changes
consistent with secondary hyperparathyroidism. The duration
of dialysis treatment was similar in both dialysis groups: 85
5.6 months in patients with OF and 84 7.7 months in those
with NBR.
Results comparing echographic and hemodynamic data be-
tween the controls and the two groups of dialysis patients are
given in Table 3. Table 4 displays the comparison of the effects
of A-V fistula occlusion in OF group and NBR group.
In comparison with the control group, the two subsets of
dialysis patients display a similar left ventricular enlargement.
However, in patients with OF, LVPWT was significantly de-
creased as compared with both controls and patients with NBR.
On the other hand, in patients with NBR, IVST was signifi-
cantly increased as compared with both controls and patients
with OF. While in the group with OF, LYM and LVM index
were similar to that of controls, in the group with NBR, it was
significantly higher than that of controls or OF. LVM/LVV
ratio was decreased only in the group with OF. As shown in
Figure 1B, in patients with NBR, the correlation between
Table 1. Blood chemistry data in dialysis patients with OF and NBR
Dialysis OF Dialysis NBR
Values are mean SD. For abbreviations see Table 1.
a P < 0.001 vs. controls and NBR
Controls
(1)
Dialysis OF
(2)
Dialysis NBR
(3)
P value
lvs.2 lvs.3 2vs.3
Sex ratio men/women 26/24 18/17 16/15 — — —
Age years 44.4 11.4 45,6 13.1 49.2 11.7 — — —
Body surface area m2 1.80 0.13 1.64 0.20 1.66 0.17 <0.001 <0.001 —
Systolic BP mm Hg 140.4 17.9 150.2 16.1 139.8 16.8 <0.01 — <0.01
Diastolic BP mm Hg 82.1 10.1 80.0 12.1 77.0 12.0 — — —
LV diastolic diameter cm 5.10 0.47 5.50 0.57 5.65 0.55 <0.001 <0.001 —
LV systolic diameter cm 3.14 0.45 3.45 0.51 3.50 0.60 <0.001 <0.001 —
LV diastolic wall thickness cm 0.80 0.12 0.70 0.12 0.82 0.11 <0.001 — <0.001
LV systolic wall thickness cm 1.23 0.14 1.26 0.21 1.35 0.19 <0.01 <0.01
Interventricular diastolic septal thickness cm 0.87 0.17 0.88 0.14 0.97 0.14 — <0.01 <0.01
LV diastolic volume index mi/m2 76.1 22.2 111.0 26.3 116.1 32.1 <0.001 <0.001 —
LV mass index g/m2 102.0 29.0 117.0 36.0 152.7 40.6 — <0.001 <0.001
LV mass/volume ratio 1.39 0.27 1.12 0.19 1.31 0.28 <0.001 — <0.001
Heart rate beats/mm 70.4 12.4 82.6 12.5 70.2 10.0 <0.001 — <0.001
Fractional shortening 95 36.3 4.1 37.6 4.9 38.4 5.5 — — —
Ejection fraction % 65.5 5.3 67.5 6.7 67.0 6.6 — — —
LVET msec 300.0 23.7 276.0 36.5 333.6 42.3 <0.01 <0.001 <0,001
VCF cjrc/sec 1.22 0.20 1.39 0.27 1.18 0.29 <0.01 — <0.01
End-systolic stress dynes/cm2 85.2 24.2 102.8 26.1 82.1 28.2 <0.01 <0.01
left ventricular; LVET, left ventricular ejection-time; VCF, velocity of circumferential fiber-
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Table 4. Functional consequence of A-V fistula occlusion in hemodialysis patients
Fistula pa Dialysis OF pb Dialysis NBR pa
Systolic BP mm Hg
Diastolic BP mm Hg
Heart rate beats/mm
LVET msec
VCF circle/sec
Open
Occluded
Open
Occluded
Open
Occluded
Open
Occluded
Open
Occluded
<001
<0.001
<0.001
<0.01
<0.01
149,0 14.0
154.0 17.2
79.2 7.7
84.1 9.0
82.6 12.5
80.0 11.2
276.0 36.5
290.0 36.2
1.39 0.27
1.34 0.24
<0.01
<0.01
(—)
(—)
<0.001
<0.001
<0.01
<0.01
<0.01
<0.001
138.3 14.1
143.0 14.2
80.8 6.7
84.5 8.4
70.2 10.0
67.9 12.8
333.6 42.3
341.2 31.0
1.18 0.29
1.09 0.22
<0.01
<0.001
<0.02
<0.01
Values are means SD. Arterial pressure is the casual blood pressure measured during echocardiographic study. For abbreviations see Table 3.
a p values before vs. after fistula occlusion
b P values in OF vs. NBR groups
OF group
y=0.006x + 0.30
r=0.476
P<0.0l
Serum parathormone, pg/mi Osteoclastic resorption
surfaces, %
Fig. 2. Correlations between left ventricular mass indexes and both
serum iPTH (A) and osteoclastic resorption surfaces (B) in the overall
dialysis patients population. Full circles (•) symbolize NBR group
patients; open circles (0) symbolize OF group patients.
systolic arterial pressure and LVM/LVV ratio was similar to
that observed in controls. While in patients with OF, although
the correlation between systolic pressure and LVM/LVV ratio
was also significant (P < 0.001), it exhibited a downward shift
as compared to controls and NBR groups. As Figure 2 displays,
NBR group Fig. 1. Correlation between systolic blood
v=0.009x 0.07 pressure and left ventricular mass-to-volume
poooi ratio in control subjects (A) and hemodialysis
___________ patients (B). Full circles and line (——)
140 160 180 symbolize NUR group patients; open circles
and dotted line (....O....) symbolize OF group
patients.
when the overall population of dialysis patients is studied
together, significant correlations between LVM (r =
—0.58, P <
0.001) or LVM index and both iPTH and the extent of osteo-
clastic bone resorption are observed.
Hemodynamically, patients with OF had an increased sys-
tolic arterial pressure, an increased heart rate, a shorter left
ventricular ejection time, an increased VCF and a higher end-
systolic stress as compared with patients with NBR (Table 3).
As displayed on Figure 3A, a positive correlation was observed
in all dialysis patients between serum iPTH and heart rate (P <
0.001), and an inverse correlation was observed between oste-
oclastic resorption and left ventricular ejection time (Fig. 3B)
(P < 0.001).
In addition, as shown in Figure 4, while a significant inverse
correlation between VCF and end-systolic stress was observed
in both controls (Fig. 4A) and dialysis patients (Fig. 4B), a
significant upward shift of the correlation was noted in patients
with OF as compared with both NBR (P < 0.001) and controls
(P < 0.001). This correlation was similar in controls and NBR
group. In dialysis patients, there was not a correlation between
iPTH and systolic pressure. Finally, Table 4 displays the data
demonstrating that temporary A-V fistula occlusion had a
comparable hemodynamic effect in OF group than in NBR
group.
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Serum parathormone, pg/mi Osteoclastic resorption surfaces, %
Fig. 3. Correlations between serum iPTH and
heart rate (A) andbetween osteoclastic
resorption surfaces and left ventricular
ejection-time (B) in the overall dialysis patient
10 population. Full circles (•) symbolize NBR
group patients; open circles (0) symbolize OF
group patients.
Discussion
In the present study, echocardiographic evaluation in hemo-
dialysis patients indicates the presence of an enlargement of the
left ventricle. The myocardial hypertrophy anf left ventricular
functional dynamics are different according to the presence or
absence of active secondary hyperparathyroidism evaluated on
the basis of hormonal abnormalities and histological signs of
osteitis fibrosa. Patients with NBR are characterized by a left
ventricular dilation and an increase in left ventricular mass; the
LVM/LVV ratio is normal and is correlated with systolic blood
pressure in a similar way as in control subjects. Patients with
OF are characterized by an inadequate ventricular response to
pressure load, as reflected by myocardial dilation out of pro-
portion to ventricular mass. These patients have a low LVM/
LVV ratio and, in addition, they have a downward shift of the
regression line for blood pressure—LVM/LVV ratio correla-
tion. Furthermore, dialysis patients with OF have an increased
heart rate, an increased VCF and a higher systolic arterial
pressure.
An enlargement of the left ventricle is a frequent finding
observed in hemodialysis patients [22—261. The most obvious
reason for the ventricular dilation would be the chronic flow
overload. In the absence of overt fluid overload, the role of
chronic anemia and the dialysis fistula seem determinant [10].
An increase in LVM is also frequently observed in hemodi-
alysis patients Eli, 23, 24, 261 (Table 1). From the available data
in the literature, the frequency, severity and physiopathology of
this myocardium findings are not clear. In general, in these
studies, dialysis patients have been randomly selected, includ-
ing patients with hypertension or with cardiovascular clinical
abnormalities. In addition, some studies lack a control group
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Fig. 4. Correlation between end-systolic stress
and velocity of circumferential fiber
shortening in control subjects (A) and
hemodialysis patients (B). Full circles and line
(—•—) symbolize NBR group patients; open
circles and dotted line (....O....) symbolize
OF group patients.
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matched for sex, age and blood pressure. This is of importance
since, even in a normal population, the range of arterial blood
pressure is a determinant of the left ventricular thickness and
mass [14, 181. Nevertheless, once our patients were matched
with a control population, there was a clear increase in LVM
(>125 g/m2 [18]) in 37 patients (56.1%). The use of a constant
factor for cardiac density in the calculation of cardiac mass in
controls and dialysis patients is unlikely to be responsible for
this abnormality, since the ratio of the LVPWT to the left
ventricular radius (h/r ratio) which has a similar pathophysio-
logic meaning as mass-to-volume ratio [10], is also decreased in
dialysis patients. It is of interest that once dialysis patients are
separated according to the magnitude of bone resorption,
significant differences are observed between the two dialysis
groups, despite similar levels of anemia and A-V fistula flow.
A constant relationship between systolic arterial blood-pre-
ssure and LVM/LVV ratio (or ventricular wall thickness to
ventricular radius ratio) is observed in normal growing children
[27], adults with normal heart, trained athletes [28], normal
pregnant women [29] and patients with compensated, chronic
volume overload [30, 31]. The degree to which the left ventri-
cular mass is appropriate for the chamber size is reflected in the
positive relationship between ventricular or arterial blood pres-
sure and mass-to-volume ratio [32] (Fig. 1A). The present study
shows that dialysis patients with NBR have a dilated left
ventricle with an appropriate increase in LVM. In addition, the
mass-to-volume ratio is similar to that of control subjects, and
they have a relationship between systolic blood pressure and
mass-to-volume ratio which is comparable to that of control
subjects (Fig. lB). On the other hand, patients with OF, though
they have a similar degree of left ventricular dilatation and a
higher systolic blood pressure, their left ventricular mass is not
increased. Furthermore, the significant correlation between
systolic arterial pressure and LVM/LVV ratio observed in this
group (Fig. 1B) is shifted downward indicating an inadequate
ventricular hypertrophy [32].
LVM is dependent on many factors including sex, age, body
surface area, blood pressure, blood viscosity, volume load and
humoral factors [33]. Except for a higher systolic blood pres-
sure, the only apparent difference between the two dialysis
groups was increased iPTH levels in patients with OF. A
significant inverse correlation between serum iPTH or osteo-
clastic bone resorption and ventricular mass or mass-to-volume
ratio was observed, suggesting the possible role of PTH on
myocardial response to pressure load. Experimental data indi-
cate that PTH may affect myocardium. Thus, in uremic ani-
mals, parathyroidectomy prevents the appearence of myocar-
dial calcium deposits, myocardial cell necrosis and tissue fi-
brosis [34, 35]. Calcific cardiomyopathy and severe metastatic
calcifications of the myocardium have been also described in
patients with advanced renal failure and overt secondary hyper-
parathyroidism [36, 37]. An inverse correlation has been ob-
served in dialysis patients between the extent of hyperparathy-
roidism bone lesions and LVPWT or h/r ratio [10].
In comparison with normal controls and dialysis patients with
NBR, patients with OF have an increased heart rate, a de-
creased left ventricular ejection-time, an increased systolic
ejection-index, a higher systolic blood-pressure, and a higher
end-systolic stress. Furthermore, when the correlation between
end-systolic stress and VCF is compared in these groups,
patients with OF have a higher shortening velocity for a given
systolic wall stress (Fig. 4), that is, they have a higher "con-
tractility". As the increased shortening velocity is mainly due
to decreased ejection time, the positive inotropic effect and
increased heart rate might be related to the same factor(s). It
appears that the differences in cardiac function of patients with
OF as compared with NBR cannot be explained in terms of
differences in A-V fistula flow, anemia, body size or sex. The
correlation observed between iPTH and heart rate or between
bone resorption surfaces and ventricular ejection time suggests
that the increase in heart rate observed in patients with OF may
be related to the action of P1'H. Experimental studies have
shown that PTH increased the beating rate of isolated heart
cells in cultures [7]. Furthermore, PTH stimulated cAMP
production by myocardial cells. This action was prevented by
verapamil and it was independent of the effects of a- or
/3-adrenergic agonists [7]. Also, in dialysis patients, parathy-
roidectomy induces a decrease in heart rate [13].
Patients with OF have a higher VCF and an increased
"contractility" as indicated by the upward reseting of the
systolic stress—VCF relationship (Fig. 4B). Experimental stud-
ies have demonstrated that PTH interfers with myocardial
contractility. Katho et al have observed a positive inotropic
action of synthetic bovine PTH on the isolated papillary muscle
of the rat heart [38]. This effect was partially antagonized by
propranolol, and completely blocked by verapamil. Further-
more, Lhoste et al [39] observed, on the isometric contractile
force of isolated guinea-pig auricles, an inhibitory action of
PTH (amino-terminal fragment) on the cardio-depressant effect
of propranolol and verapamil. This inotropic effect of PTH is
probably the result of hormonal binding to specific receptors,
which leads to an increased entry of calcium into the myocar-
dial cells and the release of endogenous myocardial norepineph-
rifle [38, 39]. Clinical studies evaluating PTH effect on the heart
are controversial. Thus, Gafter et al [13] have not found any
changes in long-term cardiac performance after parathyroidec-
tomy in dialysis patients; however, data on calcium and PTH
activity were not reported. On the other hand, Drueke et al
have claimed an improvement in myocardial function following
parathyroidectomy in uremic patients [12]. These apparent
discrepancies may be related to patients selection and different
initial myocardial performance of the patients. Increased myo-
cardial oxygen consumption may be present in the hyperpara-
thyroid patients as the result of an increase in systolic wall
stress [401, tachycardia and increased contractility. Recently,
Baczynski et al have demonstrated that PTH impairs myocar-
dial energy production, transfer and utilization in rats [9]. On
isolated heart mitochondria, PTH inhibits phosphorylation and
uncoupled oxydative phosphorylation, and this effect is dose-
dependent [8].
The higher systolic blood pressure observed in dialysis
patients with OF does not seem to be primarily related to
increased PTH level or activity. Thus, no correlation was
observed with serum iPTH or bone histology. Although primary
hyperparathyroidism is frequently associated with chronic hy-
pertension, the long-term hypercalcemia may play a role in the
hypertension. On the other hand, hypercalcemia was not pre-
sent in our patients with OF, and the calcemia was comparable
to that of controls or NBR group. Systolic blood pressure is
determined by multiple factors [41]: peak ejection velocity
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(which in turn is influenced by cardiac performance), aortic
pulse wave velocity (principally dependent upon aortic and
arterial distensibility), and wave reflection. Thus, systolic pres-
sure may be considered as the superimposition of an incident
wave (depending upon ventricular ejection) and a reflected
wave (depending upon the pulse wave velocity and the length
between the heart and points of reflection) [42]. Although pulse
wave velocity and reflections which depend upon physical
properties of the arterial system were not evaluated in the
present study, the decrease in left ventricular ejection-time, and
the increase in velocity of fiber shortening observed in dialysis
patients with OF suggest that increased systolic pressure may
be the result of the "hyperkinetic" left ventricular function.
The hyperkinetic circulation observed in patients with sec-
ondary hyperparathyroidism could also suggest a hyper f3-
adrenergic state. However, there is evidence in the literature
for a myocardial end-organ resistance to catecholamines. In-
deed, an attenuated response of heart rate to isoproterenol and
propranolol in hemodialyzed patients, which improves after
parathyroidectomy has been documented by Ulman et al [43].
Furthermore Brodde and Daul [44] have observed a failure of
isoprenaline to increase plasma renin activity in dialyzed pa-
tients, due to a post-receptor defect, supporting the idea of
reduced sympathetic system sensitivity and effects.
The present data, though suggestive, does not establish a
cause-effect relationship between the myocardial abnormalities
and the severity of hyperparathyroidism. Thus, an alternative
possibility could be that patients with overt OF may, as a result
of an increased bone activity, impose a burden in the myocar-
dium and lead to the above mentioned abnormalities.
Nevertheless, the biological action of PTH on the myocar-
dium is not fully understood. The present study provides
further support for the notion that the elevated blood levels of
PTH in patients with chronic uremia may affect the myocardial
contractility and/or hypertrophy. Whether this is a direct or
indirect effect remains to be proven. Further studies in this area
are needed.
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